Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

1391 results about "Carboxamide" patented technology

In organic chemistry carboxamides (or amino carbonyls) are functional groups with the general structure R-CO-NR'R′′ with R, R', and R′′ as organic substituents, or hydrogen. Two amino acids, asparagine and glutamine, have a carboxamide group in them. The properties and reactivity of the carboxamide group arise from the hydrogen bonding capabilities of the -NH₂ group as well as the carbonyl oxygen. Furthermore, the carbon atom in a carboxamide has a low-lying LUMO that is capable of accepting electron density from the nonbonding lone pair on the nitrogen, weakening the carbon-oxygen bond.

Macrocyclic compounds as KRAS mutant inhibitors for the treatment of cancer

The present invention relates to four specific macrocyclic compounds for use as inhibitors of KRAS mutant for the treatment of cancer. Example (1): 1-[4-(dimethylamino)-4-methyl-pent-2-ynoyl]-N-[(1S)-1-[[(6S,8S,14S)-22-ethyl-25-fluoro-(21M)-21-[2-[(1S)-1-methoxyethyl]-3-pyridyl]-18,18-dimethyl-9,15-dioxo-5,16-dioxa-2,10,22,28-tetrazapentacyclo[18.5.2.12,6.110,14.023,27]nonacosa-1(26),20,23(27),24-tetraen-8-yl]carbamoyl]-2-methyl-propyl]-4-fluoro-N-methyl-piperidine-4-carboxamide.
Owner:F HOFFMANN LA ROCHE & CO AG +1

3-phenylisoxazoline-5-carboxamide compound, and preparation method therefor, herbicidal composition thereof and use thereof

PCT designated stage expiredWO2024251055A1BiocideOrganic chemistryPesticides/herbicidesFormamide
The present invention relates to the field of pesticide herbicides, and specifically relates to a 3-phenylisoxazoline-5-carboxamide compound as represented by general formula (I), a stereoisomer thereof, an agriculturally acceptable salt thereof, a preparation method therefor, an herbicidal composition and the use thereof in the field of plant protection. X1, X2, X3, R1, Z and G are as defined herein.
Owner:JIANGSU FLAG CHEM IND CO LTD

Application of compound NSC-32 in prevention and treatment of magnaporthe oryzae

The invention relates to the field of prevention and treatment of plant filamentous fungal diseases, in particular to an application of a compound NSC-32 (N-[(5Z)-4-oxo-5-(phenylmethylidene-1, 3-thiazolidin-3-yl) pyridin-4-carboxamide) in prevention and treatment of magnaporthe oryzae, and a preparation method of the compound NSC-32 (N-[(5Z)-4-oxo-5-(phenylmethylidene-1, 3-thiazolidin-3-yl) pyridin-4-carboxamide). MoPex19 protein is used as a target spot, a compound NSC-32 is obtained through screening, and it is proved that the compound can inhibit growth of magnaporthe oryzae and reduce pathogenicity of the magnaporthe oryzae. In addition, the application object, the use method, the target specificity and the action mechanism of the compound NSC-32 are further explored, and a new green pesticide and a new thought are provided for preventing and treating the magnaporthe oryzae.
Owner:ZHEJIANG ACADEMY OF AGRICULTURE SCIENCES

Tetrahydrofuramide sodium channel regulator and application thereof in medicine

The invention provides a substituted tetrahydrofuran carboxamide derivative, salt or stereochemical isomer, a pharmaceutical composition containing the substituted tetrahydrofuran carboxamide derivative, application of the substituted tetrahydrofuran carboxamide derivative as a Nav inhibitor and application of the substituted tetrahydrofuran carboxamide derivative in preparation of drugs for treating and / or relieving pain and pain related diseases. The compound provided by the invention has the advantages of high metabolic stability, high oral absorption, better bioavailability, better activity, higher selectivity, better pharmacokinetic property, quicker effect, low side effect on central nervous system and the like.
Owner:ANDIKANG (WUXI) BIOLOGICAL TECH CO LTD

Naphthyl-containing piperidine inhibitors of SLC6a19 function

PCT designated stage expiredWO2025038949A1Metabolism disorderUrinary disorderDiseasePhenylacetones
Disclosed are naphthyl compounds comprising either a ureido piperidine-1 -carboxamide or a ureido piperidine-1 -carboxylate moiety, compositions thereof, and methods of use thereof, for treating or preventing a disease or disorder associated with abnormal levels of amino acids by modulation of SLC6A19 transport, such as phenylketonuria, hyperphenylalaninemia, diabetes and chronic kidney disease.
Owner:JNANA THERAPEUTICS INC

Crystal form of heterocyclic compound and pharmaceutical composition thereof

The invention belongs to the field of medical chemistry, and particularly relates to a crystal form of a heterocyclic compound and a pharmaceutical composition thereof. Specifically, the invention relates to a crystal form of 4-((2R, 3S, 5R)-3-(3, 4-difluoro-2-methoxyphenyl)-5-methyl-5-(trifluoromethyl) thiacyclopentane-2-formamido) pyridine-2-formamide and a pharmaceutical composition of the crystal form of 4-((2R, 3S, 5R)-3-(3, 4-difluoro-2-methoxyphenyl)-5-methyl-5-(trifluoromethyl) thiacyclopentane-2-formamido) pyridine-2-formamide. The crystal form is good in crystallinity, excellent in chemical stability and crystal form stability, high in process safety and capable of playing a good drug effect in various animal models.
Owner:SICHUAN KELUN PHARMA RES INST CO LTD

Sulfate crystal form of an amide compound, pharmaceutical composition and use thereof

The present invention belongs to the field of pharmaceutical chemistry, and relates to different sulfate crystal forms of an amide compound, namely, 1-(3-cyano-5-methylthiophene-2-yl)-N-(6-methoxy-1H-benzo[d]imidazol-2-yl)-2,5-dimethyl-1H-pyrrole-3-carboxamide, a pharmaceutical composition containing the crystal form, and uses thereof. The chemical stability and crystal stability of the sulfate crystal form are both better than those of the free base crystal form.
Owner:SHENZHEN KEYE HEALTH CO LTD

Solid form of a quinoline carboxamide compound

The present invention relates to a crystalline polymorph of the compound of formula (I) which has a powder X-ray diffraction pattern comprising at least three 2θ angle values selected from the group consisting of consisting of 7.1 ±0.2, 7.8 ± 0.2°, 8.9 ± 0.2°, 11.4 ± 0.2°, 13.5 ± 0.2°, 14.2 ± 0.2°, 14.7 ± 0.2°, 16.2 ± 0.2°, 17.7 ± 0.2°, 18.4 ± 0.2°, 20.0 ± 0.2°, 20.8 ± 0.2°, 21.2 ± 0.2°, 21.5 ± 0.2°, 22.3 ± 0.2°, 22.9 ± 0.2°, 23.6 ± 0.2°, 24.0 ± 0.2°, 24.3 ± 0.2°, 25.0 ± 0.2°, 26.2 ± 0.2°, 27.3 ± 0.2°, 27.7 10 ± 0.2°, 28.6 ± 0.2°, 29.6 ± 0.2°, 30.3 ± 0.2°.
Owner:SYNGENTA CROP PROTECITON AG

Pharmaceutical compositions comprising (2S)-n-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide

The present disclosure relates to pharmaceutical compositions suitable for oral administration, and more particularly to pharmaceutical compositions, including pharmaceutical tablet compositions, containing (2S)-N-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide (Compound A) or a pharmaceutically acceptable salt thereof.
Owner:ASTRAZENECA AB

Isoxazole-3-carboxyamide compounds for enhancing telomerase reverse transcriptase (TERT) expression

Telomerase reverse transcriptase (TERT) expression enhancing isoxazole-3-carboxamide compounds, and methods for using the same, are provided. These compounds and methods find use in a variety of applications in which increased expression of telomerase reverse transcriptase is desired.
Owner:SIERRA SCIENCES LLC

N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels

Compounds of formula (I) and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.
Owner:VERTEX PHARMACEUTICALS INC

Synthesis method and application of pyrimidone compound

The invention relates to the field of organic chemical synthesis, in particular to a synthetic method and application of pyrimidone compounds. The invention provides a synthesis method, reactants are o-amino heterocyclic formamide and triethyl orthoformate respectively, a solvent system is a hexafluoroisopropanol solvent, and a product is a heterocyclic pyrimidone compound. The reaction does not need strong acid or strong alkali conditions, does not need additional reducing agents or oxidizing agents, does not need transition metal catalysis, is economical and practical, the reaction conditions are relatively mild, and the synthesized pyrimidone compound has a good antibacterial effect.
Owner:RES INST OF CHEM DEFENSE PLA ACAD OF MILITARY SCI

Dosage forms for Tyk2 inhibitors

Stable and bioavailable formulations and dosage forms comprising a dispersion (e.g., spray-dried dispersion) of solid amorphous 6-(cyclopropancamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (Formula (I): BMS-986165) in a solid polymer matrix are provided for the treatment of auto-immune and auto-inflammatory diseases such as an inflammatory bowel disease (IBD) and psoriasis.
Owner:BRISTOL MYERS SQUIBB CO

Tetrahydrofuroylamide compound as sodium channel regulator and application of tetrahydrofuroylamide compound in medicine

The invention provides an N-(hydroxyalkyl pyridyl) tetrahydrofuran carboxamide compound, a prodrug, an oxide, a salt, a metal complex or a stereochemical isomer of a sodium channel regulator and a pharmaceutical composition containing the N-(hydroxyalkyl pyridyl) tetrahydrofuran carboxamide compound, the prodrug, the oxide, the salt, the metal complex or the stereochemical isomer. And their use as Nav inhibitors and their use in the preparation of medicaments for the treatment and / or alleviation of pain and pain-related diseases. The compound provided by the invention has the advantages of high metabolic stability, high oral absorption, better bioavailability, better activity, higher selectivity, better pharmacokinetic property, quicker effect, low cardiac side effect and the like.
Owner:ANDIKANG (WUXI) BIOLOGICAL TECH CO LTD

Composition comprising an antimicrobial agent and a carboxamide

The present invention relates to a composition comprising an antimicrobial agent (a) as defined in the claims and the description and a specific carboxamide (b) of formula (I), (I), wherein the variables are as defined in the claims and the description; to the use of said carboxamide for enhancing the antimicrobial, in particular the preserving, activity of the antimicrobial agent (a), to a method for enhancing the antimicrobial, in particular the preserving, activity of the antimicrobial agent (a), comprising using the antimicrobial agent (a) in combination with said carboxamide, and to a mixture consisting of at least one antimicrobial agent (a), at least one carboxamide compound of the formula (I) and optionally at least one solvent [different from the carboxamide compounds of the formula (I)].
Owner:BASF SE

Combinations for treatment of NASH / NAFLD and related diseases

ActiveUS12247022B2Benzoic acidDisease
The combination of (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide or pharmaceutically acceptable salt thereof, and 4-(4-(1-Isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4′-piperidine]-1′-carbonyl)-6-methoxypyridin-2-yl)benzoic acid or pharmaceutically acceptable salt thereof, for treatment of diseases, including non-alcoholic steatohepatitis (NASH), in mammals are described herein.
Owner:PFIZER INC

Novel pyridine carboxamide compounds with Anti-tubercular activity

The present invention provides novel pyridine carboxamide compounds that have anti-tubercular activity. The compounds of the invention have inhibitory action against drug sensitive as well as drug resistant M. tuberculosis infection.
Owner:TRANSLATIONAL HEALTH SCI & TECH INST

A ternary insecticidal composition for insects, pests and mites

PCT designated stage expiredWO2025150071A1BiocideAnimal repellantsPhenacylEthyl group
The present invention relates to a ternary insecticidal composition of 3-[benzoyl(methyl)amino]-N-[2-bromo-4-(1,1,1,2,3,3,3-heptafluoropropan-2-yl)- 6-(trifluoromethyl)phenyl]-2-fluorobenzamide (Component A), 4-chloro-5-ethyl-2-methyl-N-[[4-(4-methylphenoxy)phenyl]methyl] pyrazole-3-carboxamide (Component B) and at least one insecticide (Component C) demonstrating an effective and synergistic broad spectrum control of insects-pests and mites with one shot application by developing delay in resistance of hard to kill and resistant towards insects-pests and mites Further, the ternary insecticidal composition provides residual control and increases yield of treated plants due to protection against insect-pests and mites. The ternary insecticidal composition of present invention increases overall health and plant vigor and is environmentally safe.
Owner:RAJDHANI PETROCHEMICALS PRIVATE LIMITED

Deuterated pyrazolyl formamide compound as well as preparation method and application thereof

ActiveCN119285547AHigh bactericidal activityBiocideOrganic chemistry methodsChemical compoundPyrazolylchalcone
The invention relates to a deuterated pyrazolyl formamide compound as well as a preparation method and application thereof. Specifically, the compound has a structure as shown in a formula I, and has a more excellent bactericidal effect and an effect of increasing the yield. # imgabs0 #
Owner:HEFEI AISHANG AGRI TECH CO LTD +2

New solid forms of n-[(1s,2e)-1-cyclopropyl-3-(methanesulfonyl)prop-2-en-1-YL]-2- (1,1-difluoroethyl)-4- phenoxypyrimidine-5-carboxamide

PCT designated stage expiredWO2025149547A1Organic chemistryAntineoplastic agentsAcyl groupEthyl group
The present invention provides solid forms of N-[(1S,2E)-1-cyclopropyl-3- (methanesulfonyl)prop-2-en-1-yl]-2-(1,1-difluoroethyl)-4-phenoxypyrimidine-5-carboxamideide and solvates thereof, as well as therapeutic uses thereof and pharmaceutical composition comprising them.
Owner:F HOFFMANN LA ROCHE & CO AG +1

Crystalline forms of n-((1r,3s)-3-(4-acetylpiperazin-1-yl)cyclohexyl)-4-fluoro-7-methyl-1h-indole-2-carboxamide

This disclosure provides crystalline forms of N-((1R,3S)-3-(4-acetylpiperazin-1-yl)cyclohexyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide. N ((1R,3S)-3-(4-acetylpiperazin-1-yl)cyclohexyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide hydrochloride, and N-((1R,3S)-3-(4-acetylpiperazin-1-yl)cyclohexyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide hydrobromide, pharmaceutical compositions comprising these crystalline forms, methods of making these crystalline forms, and methods of treating a disease, condition, or disorder in a subject comprising administering these crystalline forms to the subject.
Owner:EPIZYME INC

Process for producing acyloxymethyl esters of (4S)-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carboxylic acid

The present invention relates to a process for preparing acyloxymethyl esters of (4S)-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxylic acid of the formula (IIa) by optical resolution of the compound of the formula (II) using a hydrolase. The invention also relates to a process for preparing (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide of the formula (Ia), wherein the process comprises the optical resolution of the compound of the formula (II) using a hydrolase. The invention additionally also relates to the use of a hydrolase in a process for preparing a compound of formula (IIa). The invention further relates to the use of a hydrolase in a process for preparing a compound of formula (Ia).
Owner:BAYER AG

Carboxamide-4-quinoline compounds with anthelmintic activity

The present invention provides novel carboxamide-4-quinoline compounds that can be used as medicaments, particularly in the treatment and prevention of diseases in animals caused by helminths.
Owner:INTERVET INT BV +1

Pharmaceutical composition and administrations thereof

The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.
Owner:VERTEX PHARMACEUTICALS INC

Dosage regimens for the treatment of autoimmune and inflammatory diseases using ly3871801

Disclosed herein are methods of treating a subject having an autoimmune or inflammatory disease, and formulations associated therewith, comprising administering to the patient a compound of (S)-5-benzyl-N-(7-(3-hydroxy-3-methylbut-1-yn-1-yl)-5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-1H-1,2,4-triazole-3-carboxamide, or a pharmaceutically acceptable salt thereof, wherein the compound or the pharmaceutically acceptable salt is administered at a dose of about 12.5 mg to about 125 mg free base equivalent of said compound per dose.
Owner:ELI LILLY & CO +1

Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof

The present disclosure relates to solid-state forms and corresponding pharmaceutical compositions of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, and methods of treatment, including treatment of rheumatoid arthritis and juvenile idiopathic arthritis using the same. The treatment methods generally comprise administering to a patient (e.g., a pediatric patient) a therapeutically effective amount of upadacitinib as a stable liquid pharmaceutical composition or a solid dosage form, at a dose based on patient body weight.
Owner:ABBVIE INC